Nanoparticles of a New Small-Molecule P-Selectin Inhibitor Attenuate Thrombosis, Inflammation, and Tumor Growth in Two Animal Models

Qiqi Feng, Mengyang Wang, Eldar Muhtar, Yaonan Wang, Haimei Zhu School of Pharmaceutical Sciences, Beijing Area Major Laboratory of Peptide and Small Molecular Drugs, Engineering Research Center of Endogenous Prophylactic of Ministry of Education of China, Capital Medical University, Beijing, 100069...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Feng Q, Wang M, Muhtar E, Wang Y, Zhu H
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2021
Materias:	p-selectin thrombosis inflammation cancer antagonist self-assembly Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/bf23ee6d385a481b96cd2fa9797631ef
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:bf23ee6d385a481b96cd2fa9797631ef
record_format	dspace
spelling	oai:doaj.org-article:bf23ee6d385a481b96cd2fa9797631ef2021-12-02T16:39:59ZNanoparticles of a New Small-Molecule P-Selectin Inhibitor Attenuate Thrombosis, Inflammation, and Tumor Growth in Two Animal Models1178-2013https://doaj.org/article/bf23ee6d385a481b96cd2fa9797631ef2021-08-01T00:00:00Zhttps://www.dovepress.com/nanoparticles-of-a-new-small-molecule-p-selectin-inhibitor-attenuate-t-peer-reviewed-fulltext-article-IJNhttps://doaj.org/toc/1178-2013Qiqi Feng, Mengyang Wang, Eldar Muhtar, Yaonan Wang, Haimei Zhu School of Pharmaceutical Sciences, Beijing Area Major Laboratory of Peptide and Small Molecular Drugs, Engineering Research Center of Endogenous Prophylactic of Ministry of Education of China, Capital Medical University, Beijing, 100069, People’s Republic of ChinaCorrespondence: Haimei ZhuSchool of Pharmaceutical Sciences, Capital Medical University, 10 Youanmenwaixitoutiao, Fengtai District, Beijing 100069, People’s Republic of ChinaTel/Fax +86-10-8391-1871Email hmzhu@ccmu.edu.cnPurpose: To assess whether the newly designed small-molecule oral P-selectin inhibitor 3S-1,2,3,4-tetrahydro-β-carboline-3-methyl aspartyl ester (THCMA) as a nanomedicine enhances antithrombosis, anti-inflammation, and antitumor activity more than the clinical trial drug PSI-697.Methods: THCMA was designed as an amphiphile containing pharmacophores of PSI-697. Its nanofeatures were explored with TEM, SEM, Tyndall effect, ζ-potential, FT-ICR-MS, and NOESY 2D 1H NMR. The P-selectin inhibitory effect of THCMA was demonstrated with molecular docking, ultraviolet (UV) spectra, and competitive ELISA. In vivo and in vitro assays — anti-arterial thrombosis, anti–venous thrombosis, anti-inflammation, antitumor growth, anti–platelet aggregation, rat-tail bleeding time, anticoagulation index, soluble P-selectin (sP-selectin) expression, and serum TNFα expression — were performed to explore bioactivity and potential mechanisms. Water solubility of THCMA was measured using UV-absorption spectra.Results: THCMA self-assembled into nanorings of approximately 100 nm in diameter. Its water solubility was about 1,030-fold that of PSI-697. THCMA exhibited more potent P-selectin inhibitory effect than PSI-697. The oral efficacy of THCMA was 100-fold that of PSI-697 in inhibiting arterial and venous thrombosis and tenfold in inhibiting inflammation. THCMA inhibited thrombosis at a dose that produces no coagulation disorders and no bleeding risk. THCMA exhibited enhanced antitumor activity over PSI-697 without systemic chemotherapy toxicity. THCMA significantly inhibited platelet aggregation in vitro and downregulated the expression levels of serum sP-selectin and TNFα in vivo.Conclusion: A new small-molecule P-selectin inhibitor, THCMA, has been successfully designed as a nanomedicine with largely enhanced oral efficacy compared to the clinical trial drug PSI-697, and thus might be developed for the oral treatment of arterial thrombosis, venous thrombosis, inflammation, and cancer-associated thrombosis.Keywords: P-selectin, thrombosis, inflammation, cancer, antagonist, self-assemblyFeng QWang MMuhtar EWang YZhu HDove Medical Pressarticlep-selectinthrombosisinflammationcancerantagonistself-assemblyMedicine (General)R5-920ENInternational Journal of Nanomedicine, Vol Volume 16, Pp 5777-5795 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	p-selectin thrombosis inflammation cancer antagonist self-assembly Medicine (General) R5-920
spellingShingle	p-selectin thrombosis inflammation cancer antagonist self-assembly Medicine (General) R5-920 Feng Q Wang M Muhtar E Wang Y Zhu H Nanoparticles of a New Small-Molecule P-Selectin Inhibitor Attenuate Thrombosis, Inflammation, and Tumor Growth in Two Animal Models
description	Qiqi Feng, Mengyang Wang, Eldar Muhtar, Yaonan Wang, Haimei Zhu School of Pharmaceutical Sciences, Beijing Area Major Laboratory of Peptide and Small Molecular Drugs, Engineering Research Center of Endogenous Prophylactic of Ministry of Education of China, Capital Medical University, Beijing, 100069, People’s Republic of ChinaCorrespondence: Haimei ZhuSchool of Pharmaceutical Sciences, Capital Medical University, 10 Youanmenwaixitoutiao, Fengtai District, Beijing 100069, People’s Republic of ChinaTel/Fax +86-10-8391-1871Email hmzhu@ccmu.edu.cnPurpose: To assess whether the newly designed small-molecule oral P-selectin inhibitor 3S-1,2,3,4-tetrahydro-β-carboline-3-methyl aspartyl ester (THCMA) as a nanomedicine enhances antithrombosis, anti-inflammation, and antitumor activity more than the clinical trial drug PSI-697.Methods: THCMA was designed as an amphiphile containing pharmacophores of PSI-697. Its nanofeatures were explored with TEM, SEM, Tyndall effect, ζ-potential, FT-ICR-MS, and NOESY 2D 1H NMR. The P-selectin inhibitory effect of THCMA was demonstrated with molecular docking, ultraviolet (UV) spectra, and competitive ELISA. In vivo and in vitro assays — anti-arterial thrombosis, anti–venous thrombosis, anti-inflammation, antitumor growth, anti–platelet aggregation, rat-tail bleeding time, anticoagulation index, soluble P-selectin (sP-selectin) expression, and serum TNFα expression — were performed to explore bioactivity and potential mechanisms. Water solubility of THCMA was measured using UV-absorption spectra.Results: THCMA self-assembled into nanorings of approximately 100 nm in diameter. Its water solubility was about 1,030-fold that of PSI-697. THCMA exhibited more potent P-selectin inhibitory effect than PSI-697. The oral efficacy of THCMA was 100-fold that of PSI-697 in inhibiting arterial and venous thrombosis and tenfold in inhibiting inflammation. THCMA inhibited thrombosis at a dose that produces no coagulation disorders and no bleeding risk. THCMA exhibited enhanced antitumor activity over PSI-697 without systemic chemotherapy toxicity. THCMA significantly inhibited platelet aggregation in vitro and downregulated the expression levels of serum sP-selectin and TNFα in vivo.Conclusion: A new small-molecule P-selectin inhibitor, THCMA, has been successfully designed as a nanomedicine with largely enhanced oral efficacy compared to the clinical trial drug PSI-697, and thus might be developed for the oral treatment of arterial thrombosis, venous thrombosis, inflammation, and cancer-associated thrombosis.Keywords: P-selectin, thrombosis, inflammation, cancer, antagonist, self-assembly
format	article
author	Feng Q Wang M Muhtar E Wang Y Zhu H
author_facet	Feng Q Wang M Muhtar E Wang Y Zhu H
author_sort	Feng Q
title	Nanoparticles of a New Small-Molecule P-Selectin Inhibitor Attenuate Thrombosis, Inflammation, and Tumor Growth in Two Animal Models
title_short	Nanoparticles of a New Small-Molecule P-Selectin Inhibitor Attenuate Thrombosis, Inflammation, and Tumor Growth in Two Animal Models
title_full	Nanoparticles of a New Small-Molecule P-Selectin Inhibitor Attenuate Thrombosis, Inflammation, and Tumor Growth in Two Animal Models
title_fullStr	Nanoparticles of a New Small-Molecule P-Selectin Inhibitor Attenuate Thrombosis, Inflammation, and Tumor Growth in Two Animal Models
title_full_unstemmed	Nanoparticles of a New Small-Molecule P-Selectin Inhibitor Attenuate Thrombosis, Inflammation, and Tumor Growth in Two Animal Models
title_sort	nanoparticles of a new small-molecule p-selectin inhibitor attenuate thrombosis, inflammation, and tumor growth in two animal models
publisher	Dove Medical Press
publishDate	2021
url	https://doaj.org/article/bf23ee6d385a481b96cd2fa9797631ef
work_keys_str_mv	AT fengq nanoparticlesofanewsmallmoleculepselectininhibitorattenuatethrombosisinflammationandtumorgrowthintwoanimalmodels AT wangm nanoparticlesofanewsmallmoleculepselectininhibitorattenuatethrombosisinflammationandtumorgrowthintwoanimalmodels AT muhtare nanoparticlesofanewsmallmoleculepselectininhibitorattenuatethrombosisinflammationandtumorgrowthintwoanimalmodels AT wangy nanoparticlesofanewsmallmoleculepselectininhibitorattenuatethrombosisinflammationandtumorgrowthintwoanimalmodels AT zhuh nanoparticlesofanewsmallmoleculepselectininhibitorattenuatethrombosisinflammationandtumorgrowthintwoanimalmodels
_version_	1718383598658125824

Nanoparticles of a New Small-Molecule P-Selectin Inhibitor Attenuate Thrombosis, Inflammation, and Tumor Growth in Two Animal Models

Ejemplares similares